Main content

Health Information

Risedronate

Drug Information

Risedronate is used to treat certain bone diseases. It is in a family of drugs known as bisphosphonates.

Common brand names:

Actonel

Summary of Interactions with Vitamins, Herbs, & Foods

Reference What Are Nutrient Interactions

Types of interactions: Beneficial Adverse Check

Replenish Depleted Nutrients

none

Reduce Side Effects

none

Support Medicine

none

Reduces Effectiveness

Reference Iron

Taking risedronate at the same time as Reference iron, Reference zinc, or Reference magnesium may reduce the amount of drug absorbed.¹ Therefore, people taking risedronate who wish to supplement with these minerals should take them an hour before or two hours after the drug.
Reference Zinc

Taking risedronate at the same time as Reference iron, Reference zinc, or Reference magnesium may reduce the amount of drug absorbed.² Therefore, people taking risedronate who wish to supplement with these minerals should take them an hour before or two hours after the drug.

Potential Negative Interaction

none

Explanation Required

Reference Calcium

Short-term treatment with risedronate in people with hyperparathydoidism—a disorder characterized by high blood levels of calcium—resulted in lower calcium blood levels.³ Additional research is needed to determine whether people taking risedronate for Paget’s disease might develop low blood calcium levels. As a precaution, people with Paget’s disease should take supplemental calcium and vitamin D if dietary intake is inadequate. However, taking risedronate at the same time as calcium supplements reduces absorption of the drug.⁴ Therefore, people taking risedronate for Paget’s disease should take calcium supplements an hour before or two hours after taking the drug.

The interaction is supported by preliminary, weak, fragmentary, and/or contradictory scientific evidence.
Reference Magnesium

Taking risedronate at the same time as Reference iron, Reference zinc, or Reference magnesium may reduce the amount of drug absorbed.⁵ Therefore, people taking risedronate who wish to supplement with these minerals should take them an hour before or two hours after the drug.

The interaction is supported by preliminary, weak, fragmentary, and/or contradictory scientific evidence.
Reference Vitamin D

Short-term treatment with risedronate in people with hyperparathydoidism—a disorder characterized by high blood levels of calcium—resulted in lower calcium blood levels.⁶ Additional research is needed to determine whether people taking risedronate for Paget’s disease might develop low blood calcium levels. As a precaution, people with Paget’s disease should take supplemental calcium and vitamin D if dietary intake is inadequate. However, taking risedronate at the same time as calcium supplements reduces absorption of the drug.⁷ Therefore, people taking risedronate for Paget’s disease should take calcium supplements an hour before or two hours after taking the drug.

The interaction is supported by preliminary, weak, fragmentary, and/or contradictory scientific evidence.

The Drug-Nutrient Interactions table may not include every possible interaction. Taking medicines with meals, on an empty stomach, or with alcohol may influence their effects. For details, refer to the manufacturers’ package information as these are not covered in this table. If you take medications, always discuss the potential risks and benefits of adding a new supplement with your doctor or pharmacist.

References

1. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc. 2000, 2504–6.

2. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc. 2000, 2504–6.

3. Reasner CA, Stone MD, Hosking DJ, et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993;77:1067–71.

4. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2000, 2504–6.

5. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc. 2000, 2504–6.

6. Reasner CA, Stone MD, Hosking DJ, et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993;77:1067–71.

7. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2000, 2504–6.

Last Review: 11-07-2012

Please read the Reference disclaimer about the limitations of the information provided here. Do NOT rely solely on the information in this article. The Aisle7 knowledgebase does not contain every possible interaction.

Reference Learn more about Aisle7, the company.

The information presented in Aisle7 is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires June 2013.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Reference Terms of Use. Reference How this information was developed to help you make better health decisions.